CJC-1295 Legit

Sources · CJC-1295

Full citation index.

Every source referenced on this site, with full bibliographic detail, DOI, and links to primary publication venues.

How to read this index

Citations are numbered as they appear throughout the site. Each entry includes the authors, journal, year, DOI, and a link to the primary source — PubMed, PMC, academic.oup.com, or the original agency or organization document. Where a PubMed ID (PMID) is available, it is linked directly to the PubMed abstract. Where a PubMed Central ID (PMCID) is available, the full text is linked via PMC.

Regulatory and policy citations (FDA, WADA, BSCG, Lexology) are linked to their source documents where publicly available. Anti-doping forensic citations are linked to their PubMed records.

This index covers human studies, animal studies, anti-doping and forensic analytical studies, regulatory proceedings, and review articles. Findings from each are described in the research, dosage, and FAQ sections of this site.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. ↗
  2. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. [Multiple-dose arm data] ↗
  3. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. [Pharmacokinetic half-life data] ↗
  4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology - Endocrinology and Metabolism. 2006;291(6):E1290-4. ↗
  5. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology - Endocrinology and Metabolism. 2006;291(6):E1290-4. [Somatotroph proliferation and GH mRNA data] ↗
  6. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  7. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. [In vitro DPP-IV resistance and receptor activity data] ↗
  8. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research. 2009;19(6):499-507. ↗
  9. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Analysis. 2010;2(11-12):609-612. ↗
  10. Timms M, Ganio K, Forbes G, Bailey S, Steel R. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Test Analysis. 2019;11(6):885-893. ↗
  11. Timms M, Ganio K, Steel R. A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. Drug Test Analysis. 2019;11(8):1224-1229. ↗
  12. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. [DAC albumin-binding mechanism and Western blot data] ↗
  13. Chapter MC, White CM, De Ridder A, Chadwick W, Martin B, Maudsley S. Chemical modification of Class II G-protein coupled receptor ligands: Frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies. Pharmacology & Therapeutics. 2010;125(1):39-54. ↗
  14. U.S. Food and Drug Administration. FDA Pharmacy Compounding Advisory Committee (PCAC) Meeting, December 4, 2024 — Briefing Documents for Bulk Drug Substances Nominated for Inclusion on the 503A Bulks List. ↗
  15. Lexology / Hogan Lovells. FDA removes certain peptide bulk drug substances from Category 2 of interim 503A bulks list and sets dates for PCAC review. Lexology. 2024. ↗
  16. BSCG (Banned Substances Control Group). CJC-1295 Use in Sports and Military Rules Explained. BSCG.org. 2023. ↗
  17. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026. ↗
  18. Mavrych V, Shypilova I, Bolgova O. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Frontiers in Aging. 2026. ↗
  19. Klinc A, Janež A, Jensterle M. Long-Term IGF-1 Maintenance in the Upper-Normal Range Has Beneficial Effect on Low-Grade Inflammation Marker in Adults with Growth Hormone Deficiency. International Journal of Molecular Sciences. 2025;26(5):2010. ↗
  20. Schally AV, Cai R, Zhang X, Sha W, Wangpaichitr M. The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders. Reviews in Endocrine and Metabolic Disorders. 2024. ↗
  21. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. ↗
  22. GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron. Journal of Clinical Endocrinology & Metabolism. 2002. ↗
  23. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity. Journal of Clinical Endocrinology & Metabolism. 2011. ↗
  24. Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nature Reviews Endocrinology. 2025;21(3):180-195. ↗
  25. ConjuChem Inc. A study to evaluate CJC-1295 in HIV patients with visceral obesity. ClinicalTrials.gov. 2006. NCT00267527. ↗
  26. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4792-4797. ↗